Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $14,558.22 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $26.09, for a total transaction of $14,558.22. Following the completion of the transaction, the director directly owned 81,042 shares in the company, valued at approximately $2,114,385.78. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Down 3.0%

Shares of NYSEAMERICAN PTHS opened at $27.16 on Friday. Pelthos Therapeutics Inc. has a 12-month low of $16.20 and a 12-month high of $37.50. The stock has a market cap of $94.52 million, a PE ratio of -1.32 and a beta of 3.10. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The company’s 50-day simple moving average is $26.87.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The business had revenue of $10.91 million for the quarter. On average, sell-side analysts forecast that Pelthos Therapeutics Inc. will post -12.63 EPS for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PTHS. Ikarian Capital LLC lifted its position in shares of Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after purchasing an additional 193,307 shares in the last quarter. J. Goldman & Co LP acquired a new position in shares of Pelthos Therapeutics in the fourth quarter valued at approximately $2,418,000. Boothbay Fund Management LLC increased its stake in Pelthos Therapeutics by 279.8% during the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares during the period. Cantor Fitzgerald L. P. acquired a new stake in Pelthos Therapeutics during the 4th quarter worth approximately $1,085,000. Finally, Diadema Partners LP lifted its holdings in Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after buying an additional 14,502 shares in the last quarter. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Cantor Fitzgerald began coverage on Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Finally, Oppenheimer lifted their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.80.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).